ERIS · Eris Lifesciences Ltd · Biotechnology & Drugs
ERIS · Eris Lifesciences Ltd · Biotechnology & Drugs
As of 05 Nov close
52-week range
29.3% below 52-week high
52-week range: as of 05 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 52 days old
Revenue (latest Q)
₹873 Cr
Revenue YoY
PAT YoY
+20.7%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
Not available from data source
P/S (TTM)
5.8
Sector P/E
36.3
Dividend yield
+0.5%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| ERIS (this stock) | 30.6 | Not available from data source | +19.9% | +16.5% | 0.6 | +0.5% |
| Sun Pharmaceutical Industries | 38.4 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 72.7 | 19.2 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
rising 1q
FII
falling 3q
MF
18.88% (+0.66pp)
rising 1q
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
No bulk/block deals in the last 12 months.
News timeline
- lowthehindubusinessline.com· 26 Oct 2026, 05:29 pmEris Lifesciences profit rises 39% to ₹187 crore in Q2
- lowbusiness-standard.com· 26 Oct 2026, 10:16 amQ2 results: Paytm, REC, Tata Consumer Products among 98 firms on October 26
- loweconomictimes.indiatimes.com· 29 Sept 2026, 05:46 pmMedico Remedies among 5 Healthcare stocks hitting 52-week low; slipped up to 48% in a month - New Bottoms
Concalls & investor presentations
AI-generatedKey takeaway: Eris Lifesciences Limited's investor presentation for Q2 and H1 FY27 highlights revenue growth of 14.1% YoY in Domestic Branded Formulations (DBF) with EBITDA margin at 35.7%, down 191 bps YoY. The DBF segment reported a 14.2% YoY revenue increase in H1 FY27, with EBITDA margin at 35.2%. The company noted a sequential improvement in gross margin, rising 100 bps from Q1 to Q2 FY27, attributed to the commercialization of the Bhopal facility and out-licensing to Zorvia Healthcare. Excluding Zorvia, DBF growth reached 16.5% in Q2. In the International Business, the EU CAPA shutdown is planned for Q3, with no cancellations in the CDMO pipeline. The Swiss Parenterals unit's construction is on track, with production expected by April 2027. Consolidated revenue grew 12.6% YoY in Q2, with PAT up 39.2% YoY. The company reported a 10-day reduction in consolidated debtor days and a net debt reduction of ₹111 cr in H1. The presentation includes forward-looking statements about future performance, subject to risks and uncertainties.
The summary presents factual financial results, operational updates, and forward-looking statements without overtly positive or negative language.
Sourced from an exchange-filed presentation, dated 26 Oct 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Eris Lifesciences Limited announced that the transcript of the Analyst and Investor call, which took place following the financial results announcement for the quarter ended June 30, 2026, is now available on their website. The document provided the relevant URL for accessing the transcript and included details about the company's compliance officer. Management communicated this information formally to both the BSE and NSE.
The document conveyed factual information regarding the availability of the earnings call transcript.
Sourced from an exchange-filed transcript, dated 04 Aug 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Eris Lifesciences Limited reported financial highlights for Q1 FY27, showing a 14.2% year-over-year increase in revenue for Domestic Branded Formulations (DBF), reaching ₹801 crore, and a consolidated revenue growth of 13% to ₹873 crore. The presentation indicated a consolidated PAT growth of 14.5%, amounting to ₹143 crore. Management noted that 7 out of 10 therapies in their portfolio achieved double-digit growth rates. The company highlighted its market share gains in the insulin segment, increasing from 9% to 16% since the Biocon acquisition. Additionally, Eris established a leading position in the GLP-1 market with a 21% share in prescriptions. The document outlined key priorities for the upcoming quarters, including enhancing growth in the OAD and Cardiac segments and entering the insulin analogs market. The presentation concluded with a summary of the shareholding pattern, indicating a strong promoter presence at 54.14%.
Management emphasized strong revenue and profit growth alongside market share gains.
Sourced from an exchange-filed presentation, dated 29 Jul 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: The document is a notification from Eris Lifesciences Limited regarding the availability of the transcript for the Analyst and Investor call held after the announcement of financial results for the quarter and year ended March 31, 2026. The transcript can be accessed on the company's website. The communication is signed by Milind Talegaonkar, the Company Secretary and Compliance Officer.
The document provided factual information about the availability of the earnings call transcript.
Sourced from an exchange-filed transcript, dated 26 May 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Eris Lifesciences Limited announced that the transcript of the Analyst and Investor call, which took place following the financial results announcement for the quarter and nine months ended December 31, 2025, is now available on their website. The document provided the necessary details for accessing the transcript, including the URL. Milind Talegaonkar, the Company Secretary and Compliance Officer, signed off on the communication.
The document conveyed information about the availability of the earnings call transcript without emphasizing any particular sentiment.
Sourced from an exchange-filed transcript, dated 20 Feb 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Eris Lifesciences Limited reported its Q3 and 9M FY26 financial highlights in the investor presentation dated February 13, 2026. The presentation indicated that the Domestic Branded Formulations (DBF) revenue for Q3 FY26 was Rs. 696 crore, reflecting a 10% year-over-year growth, while the 9M revenue reached Rs. 2,106 crore, also up 10% year-over-year. The DBF EBITDA for Q3 was Rs. 254 crore, with a margin of 36.5%, and for 9M it was Rs. 781 crore, with a margin of 37.1%. Management noted a strategic decision to discontinue non-core brands, which is anticipated to impact DBF revenue by approximately 2% in FY27 but improve operating profits. The international business segment showed a strong performance with a 45% growth in Q3 revenue, reaching Rs. 111 crore. The presentation also highlighted ongoing investments in manufacturing and product development, particularly in the insulin segment.
Management emphasized strong revenue growth and strategic improvements.
Sourced from an exchange-filed presentation, dated 13 Feb 2026. Summary is RedixFi-generated and distinct from investment advice.
AI Summary of Annual Report
AI-generatedEris Lifesciences Limited's annual report for FY2025-26 highlights the company's strategic focus on expanding its presence in emerging therapeutic areas such as Insulins and GLP-1, leveraging its strong brand portfolio and prescription ranks. The report emphasizes the company's commitment to employee welfare through various social security benefits, training programs, and inclusive workplace initiatives. Additionally, the company outlines its robust risk management framework and corporate governance practices, ensuring compliance with regulatory requirements and maintaining stakeholder trust.
- Expansion in emerging specialties like Insulins, GLP-1, Women’s Health, and CNS to drive future growth.
- Commitment to employee welfare through enhanced social security benefits, training programs, and inclusive workplace culture.
- Robust risk management and corporate governance practices to ensure regulatory compliance and stakeholder trust.
Key takeaway: Eris Lifesciences is strategically expanding into high-growth therapeutic areas while maintaining a strong focus on employee welfare and robust risk management to ensure sustainable growth.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Regulatory Action (1 item); Default / Covenant Breach (1 item)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Regulatory Action
1 occurrenceRecent (last 12 months)
The company received monetary penalties from BSE Limited and National Stock Exchange of India Limited for non-compliance with board composition requirements under SEBI regulations. Penalties amounted to ₹65,000 and ₹3,60,000 plus GST.
Default / Covenant Breach
1 occurrenceOlder (3+ years ago)
The company has income tax dues under the Income Tax Act for FY 2016-2017 and FY 2017-2018, with disputes pending before the Commissioner of Income Tax (Appeal), Ahmedabad, and these dues are more than six months in arrears as of March 31, 2023.
Routine disclosures
Contingent Liability
3 occurrencesRecent (last 12 months)
The company has disclosed the impact of pending litigation on its financial position as at 31 March 2026, as detailed in note 33 to the standalone financial statements.
Earlier (1-3 years ago)
The company has provided guarantees to banks on behalf of its subsidiaries, including Eris Therapeutics Limited, Eris Healthcare Private Limited, and Eris M.J.Biopharm Private Limited, as disclosed in the financial statements.
Older (3+ years ago)
The company has a contingent liability of ₹8.40 million related to unexecuted contracts on the capital account, net of advances.
Related-Party Transaction
3 occurrencesRecent (last 12 months)
The company acquired the remaining 30% equity stake in its subsidiary Swiss Parenterals Limited from Mr. Naishadh Shah, a related party, through a share swap arrangement. The transaction was on an arm's length basis and in compliance with applicable laws after obtaining necessary approvals.
Earlier (1-3 years ago)
The company has disclosed transactions with related parties, including loans given and received, sales of finished goods, purchases of raw materials, and royalty income and expenses with entities such as Eris M J Biopharm Private Limited, Eris Healthcare Private Limited, and others.
Older (3+ years ago)
The company has transactions with related parties, including loans given and received, investments in preference shares, and various service and royalty incomes and expenses with subsidiaries like Eris M J Biopharm Private Limited and Aprica Healthcare Limited.
Management & Board Governance
1 occurrenceOlder (3+ years ago)
Ms. Vijaya Sampath, an Independent Director, resigned from the Board of the Company with effect from July 19, 2022.
Promoter Share Pledge
1 occurrenceRecent (last 12 months)
12.29% of promoter holding pledged (quarter 2026-Q3 as of 2026-07-18).